Open accessproteomic serum biomarkers and their potential application in cancer screening programs

International Journal of Molecular Sciences

Volumn 11, Issue 11, 2010, Pages 4175-4193

  Huijbers, Anouck ^a   Velstra, Berit ^a   Dekker, Tim J A ^a   Mesker, Wilma E ^a   van der Burgt, Yuri E M ^a   Mertens, Bart J ^a   Deelder, André M ^a   Tollenaar, Rob A E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Breast cancer; Colorectal cancer; Magnetic beads; Maldi tof; Mass spectrometry; Proteomics; Screening; Seldi tof

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; COMPLEMENT COMPONENT C3A; INTER ALPHA TRYPSIN INHIBITOR; NEUTROPHIL PEPTIDE 1; NEUTROPHIL PEPTIDE 2; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; TUMOR PROTEIN;

ARTICLE; AUTOMATION; BLOOD ANALYSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; EARLY DIAGNOSIS; HUMAN; MAMMOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SIGMOIDOSCOPY; SOLID PHASE EXTRACTION; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; BREAST TUMOR; COLORECTAL TUMOR; FEMALE; MAGNETIC BEADS; MALDI-TOF; MALE; METHODOLOGY; REVIEW; SCREENING; SELDI-TOF;

BIOMARKER; BREAST CANCER; COLORECTAL CANCER; MAGNETIC BEADS; MALDI-TOF; MASS SPECTROMETRY; PROTEOMICS; SCREENING; SELDI-TOF;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650976921     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11114175     Document Type: Article

References (79)

1. SEER: Surveillance Epidemiology and End Results Program; National Cancer Institute: Bethesda, MD, USA, 2006. Available online: http://seer.cancer.gov/ (accessed on 16 October 2010).
2. Pepe, M.S.; Etzioni, R.; Feng, Z.; Potter, J.D.; Thompson, M.L.; Thornquist, M.; Winget, M.; Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93, 1054-1061.
3. Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, M.; Schwartz, S.; Reid, B.; Radich, J.; Anderson, G.; Hartwell, L. The case for early detection. Nat. Rev. Cancer 2003, 3, 243-252.
4. Srinivas, P.R.; Kramer, B.S.; Srivastava, S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001, 2, 698-704.
5. Petricoin, E.F.; Liotta, L.A. Proteomic analysis at the bedside: Early detection of cancer. Trends Biotechnol. 2002, 20, S30-S34.
6. Srinivas, P.R.; Verma, M.; Zhao, Y.; Srivastava, S. Proteomics for cancer biomarker discovery. Clin. Chem. 2002, 48, 1160-1169.
7. Wulfkuhle, J.D.; Liotta, L.A.; Petricoin, E.F. Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 2003, 3, 267-275.
8. Aebersold, R.; Mann, M. Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
9. Ikonomou, G.; Samiotaki, M.; Panayotou, G. Proteomic methodologies and their application in colorectal cancer research. Crit. Rev. Clin. Lab. Sci. 2009, 46, 319-342.
10. Veronesi, U.; Boyle, P.; Goldhirsch, A.; Orecchia, R.; Viale, G. Breast cancer. Lancet 2005, 365, 1727-1741.
11. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
12. Peto, R.; Boreham, J.; Clarke, M.; Davies, C.; Beral, V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000, 355, 1822.
13. Astley, S.M. Computer-based detection and prompting of mammographic abnormalities. Br. J. Radiol. 2004, 77, S194-S200.
14. Benson, S.R.; Blue, J.; Judd, K.; Harman, J.E. Ultrasound is now better than mammography for the detection of invasive breast cancer. Am. J. Surg. 2004, 188, 381-385.
15. Roder, D.; Houssami, N.; Farshid, G.; Gill, G.; Luke, C.; Downey, P.; Beckmann, K.; Iosifidis, P.; Grieve, L.; Williamson, L. Population screening and intensity of screening are associated with reduced breast cancer mortality: Evidence of efficacy of mammography screening in Australia. Breast Cancer Res. Treat. 2008, 108, 409-416.
16. Antman, K.; Shea, S. Screening mammography under age 50. JAMA 1999, 281, 1470-1472.
17. Li, J.; Orlandi, R.; White, C.N.; Rosenzweig, J.; Zhao, J.; Seregni, E.; Morelli, D.; Yu, Y.; Meng, X.Y.; Zhang, Z. et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 2005, 51, 2229-2235.
18. Brennan, M.E.; Houssami, N.; Lord, S.; Macaskill, P.; Irwig, L.; Dixon, J.M.; Warren, R.M.; Ciatto, S. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: Systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J. Clin. Oncol. 2009, 27, 5640-5649.
19. Weinstein, S.P.; Localio, A.R.; Conant, E.F.; Rosen, M.; Thomas, K.M.; Schnall, M.D. Multimodality screening of high-risk women: A prospective cohort study. J. Clin. Oncol. 2009, 27, 6124-6128.
20. Kriege, M.; Brekelmans, C.T.; Obdeijn, I.M.; Boetes, C.; Zonderland, H.M.; Muller, S.H.; Kok, T.; Manoliu, R.A.; Besnard, A.P.; Tilanus-Linthorst, M.M. et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res. Treat. 2006, 100, 109-119.
21. Gotzsche, P.C.; Nielsen, M. Screening for breast cancer with mammography. Cochrane. Database. Syst. Rev. 2009, 4, CD001877.
22. Bresalier, R.S. Early detection of and screening for colorectal neoplasia. Gut Liver 2009, 3, 69-80.
23. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer Statistics, 2010. CA Cancer J. Clin. 2010, doi:10.3322/caac.20073.
24. de Noo, M.E.; Liefers, G.J.; Tollenaar, R.A. Translational research in prognostic profiling in colorectal cancer. Dig. Surg. 2005, 22, 276-281.
25. Wang, Q.; Shen, J.; Li, Z.F.; Jie, J.Z.; Wang, W.Y.; Wang, J.; Zhang, Z.T.; Li, Z.X.; Yan, L.; Gu, J. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 2009, 19, doi:10.1186/1471-2407-9-287.
26. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
27. Imperiale, T.F.; Ransohoff, D.F.; Itzkowitz, S.H.; Turnbull, B.A.; Ross, M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 2004, 351, 2704-2714.
28. Yang, H.; Ge, Z.; Dai, J.; Li, X.; Gao, Y. Effectiveness of the immunofecal occult blood test for colorectal cancer screening in a large population. Dig. Dis. Sci. 2010, doi:10.1007/s10620-010- 1264-1268.
29. Rozen, P.; Comaneshter, D.; Levi, Z.; Hazazi, R.; Vilkin, A.; Maoz, E.; Birkenfeld, S.; Niv, Y. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010, 116, 2115-2125.
30. Levin, B.; Lieberman, D.A.; McFarland, B.; Andrews, K.S.; Brooks, D.; Bond, J.; Dash, C.; Giardiello, F.M.; Glick, S.; Johnson, D. et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134, 1570-1595.
31. Lieberman, D.A.; Weiss, D.G.; Bond, J.H.; Ahnen, D.J.; Garewal, H.; Chejfec, G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N. Engl. J. Med. 2000, 20, 162-168.
32. Lieberman, D.A. Clinical practice. Screening for colorectal cancer. N. Engl. J. Med. 2009, 361, 1179-1187.
33. Zavoral, M.; Suchanek, S.; Zavada, F.; Dusek, L.; Muzik, J.; Seifert, B.; Fric, P. Colorectal cancer screening in Europe. World J. Gastroenterol. 2009, 15, 5907-5915.
34. Tagore, K.S.; Lawson, M.J.; Yucaitis, J.A.; Gage, R.; Orr, T.; Shuber, A.P.; Ross, M.E. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin. Colorectal Cancer 2003, 3, 47-53.
35. Brand, R.E.; Ross, M.E.; Shuber, A.P. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. Am. J. Gastroenterol. 2004, 99, 1338-1341.
36. Syngal, S.; Stoffel, E.; Chung, D.; Willett, C.; Schoetz, D.; Schroy, P.; Jagadeesh, D.; Morel, K.; Ross, M. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer 2006, 106, 277-283.
37. Villanueva, J.; Philip, J.; Chaparro, C.A.; Li, Y.; Toledo-Crow, R.; DeNoyer, L.; Fleisher, M.; Robbins, R.J.; Tempst, P. Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome. Res. 2005, 4, 1060-1072.
38. de Noo, M.E.; Tollenaar, R.A.; Ozalp, A.; Kuppen, P.J.; Bladergroen, M.R.; Eilers, P.H.; Deelder, A.M. Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. Anal. Chem. 2005, 77, 7232-7241.
39. de Noo, M.E.; Tollenaar, R.A.; Deelder, A.M.; Bouwman, L.H. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: Hopes and fears. World J. Gastroenterol. 2006, 12, 6594-6601.
40. West-Norager, M.; Kelstrup, C.D.; Schou, C.; Hogdall, E.V.; Hogdall, C.K.; Heegaard, N.H. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 847, 30-37.
41. Baumann, S.; Ceglarek, U.; Fiedler, G.M.; Lembcke, J.; Leichtle, A.; Thiery, J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51, 973-980.
42. Omenn, G.S.; States, D.J.; Adamski, M.; Blackwell, T.W.; Menon, R.; Hermjakob, H.; Apweiler, R.; Haab, B.B.; Simpson, R.J.; Eddes, J.S. et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226-3245.
43. A gene-centric human proteome project: HUPO--the Human Proteome organization. Mol. Cell Proteomics 2010, 9, 427-429.
44. Mauri, P.; Scigelova, M. Multidimensional protein identification technology for clinical proteomic analysis. Clin. Chem. Lab Med. 2009, 47, 636-646.
45. de Noo, M.E.; Deelder, A.; van der Werff, M.; Ozalp, A.; Mertens, B.; Tollenaar, R. MALDI- TOF serum protein profiling for the detection of breast cancer. Onkologie 2006, 29, 501-506.
46. Villanueva, J.; Philip, J.; Entenberg, D.; Chaparro, C.A.; Tanwar, M.K.; Holland, E.C.; Tempst, P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004, 76, 1560-1570.
47. Whiteaker, J.R.; Zhang, H.; Eng, J.K.; Fang, R.; Piening, B.D.; Feng, L.C.; Lorentzen, T.D.; Schoenherr, R.M.; Keane, J.F.; Holzman, T. et al. Head-to-head comparison of serum fractionation techniques. J. Proteome Res. 2007, 6, 828-836.
48. Tiss, A.; Smith, C.; Camuzeaux, S.; Kabir, M.; Gayther, S.; Menon, U.; Waterfield, M.; Timms, J.; Jacobs, I.; Cramer, R. Serum peptide profiling using MALDI mass spectrometry: Avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. Proteomics 2007, 7, S77-S89.
49. Callesen, A.K.; Vach, W.; Jorgensen, P.E.; Cold, S.; Mogensen, O.; Kruse, T.A.; Jensen, O.N.; Madsen, J.S. Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: A systematic review. J. Proteome. Res. 2008, 7, 1395-1402.
50. Mertens, B.J.; de Noo, M.E.; Tollenaar, R.A.; Deelder, A.M. Mass spectrometry proteomic diagnosis: Enacting the double cross-validatory paradigm. J. Comput. Biol. 2006, 13, 1591-1605.
51. Mertens, B.J. Proteomic diagnosis competition: Design, concepts, participants and first results. J. Proteomics 2009, 72, 785-790.
52. Hu, Y.; Zhang, S.; Yu, J.; Liu, J.; Zheng, S. SELDI-TOF-MS: The proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005, 14, 250-255.
53. Fan, Y.; Wang, J.; Yang, Y.; Liu, Q.; Fan, Y.; Yu, J.; Zheng, S.; Li, M.; Wang, J. Detection and identification of potential biomarkers of breast cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 1243-1254.
54. Belluco, C.; Petricoin, E.F.; Mammano, E.; Facchiano, F.; Ross-Rucker, S.; Nitti, D.; Di, M.C.; Liu, C.; Lise, M.; Liotta, L.A. et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann. Surg. Oncol. 2007, 14, 2470-2476.
55. Callesen, A.K.; Vach, W.; Jorgensen, P.E.; Cold, S.; Tan, Q.; Depont, C.R.; Mogensen, O.; Kruse, T.A.; Jensen, O.N.; Madsen, J.S. Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: A case-control study. J. Proteome Res. 2008, 7, 1419-1426.
56. Li, J.; Zhang, Z.; Rosenzweig, J.; Wang, Y.Y.; Chan, D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002, 48, 1296-1304.
57. Vlahou, A.; Laronga, C.; Wilson, L.; Gregory, B.; Fournier, K.; McGaughey, D.; Perry, R.R.; Wright, G.L., Jr.; Semmes, O.J. A novel approach toward development of a rapid blood test for breast cancer. Clin. Breast Cancer. 2003, 4, 203-209.
58. Mathelin, C.; Cromer, A.; Wendling, C.; Tomasetto, C.; Rio, M.C. Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res. Treat. 2006, 96, 83-90.
59. Belluco, C.; Petricoin, E.F.; Mammano, E.; Facchiano, F.; Ross-Rucker, S.; Nitti, D.; Di, M.C.; Liu, C.; Lise, M.; Liotta, L.A. et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann. Surg. Oncol. 2007, 14, 2470-2476.
60. Timms, J.F.; Arslan-Low, E.; Gentry-Maharaj, A.; Luo, Z.; T'Jampens, D.; Podust, V.N.; Ford, J.; Fung, E.T.; Gammerman, A.; Jacobs, I. et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin. Chem. 2007, 53, 645-656.
61. van Winden, A.W.; Gast, M.C.; Beijnen, J.H.; Rutgers, E.J.; Grobbee, D.E.; Peeters, P.H.; van Gils, C.H. Validation of previously identified serum biomarkers for breast cancer with SELDI- TOF MS: A case control study. BMC Med. Genomics 2009, 2, 4.
62. Li, J.; Orlandi, R.; White, C.N.; Rosenzweig, J.; Zhao, J.; Seregni, E.; Morelli, D.; Yu, Y.; Meng, X.Y.; Zhang, Z. et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 2005, 51, 2229-2235.
63. Villanueva, J.; Shaffer, D.R.; Philip, J.; Chaparro, C.A.; Erdjument-Bromage, H.; Olshen, A.B.; Fleisher, M.; Lilja, H.; Brogi, E.; Boyd, J. et al. Differential exoprotease activities confer tumor- specific serum peptidome patterns. J. Clin. Invest 2006, 116, 271-284.
64. Yu, J.K.; Chen, Y.D.; Zheng, S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 2004, 10, 3127-3131.
65. Liu, X.P.; Shen, J.; Li, Z.F.; Yan, L.; Gu, J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest. 2006, 24, 747-753.
66. de Noo, M.E.; Mertens, B.J.; Ozalp, A.; Bladergroen, M.R.; van der Werff, M.P.; van de Velde, C.J.; Deelder, A.M.; Tollenaar, R.A. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 2006, 42, 1068-1076.
67. Ward, D.G.; Suggett, N.; Cheng, Y.; Wei, W.; Johnson, H.; Billingham, L.J.; Ismail, T.; Wakelam, M.J.; Johnson, P.J.; Martin, A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 2006, 19, 1898-1905.
68. Engwegen, J.Y.; Helgason, H.H.; Cats, A.; Harris, N.; Bonfrer, J.M.; Schellens, J.H.; Beijnen, J.H. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 2006, 12, 1536-1544.
69. Chen, Y.D.; Zheng, S.; Yu, J.K.; Hu, X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 2004, 10, 8380-8385.
70. Zhao, G.; Gao, C.F.; Song, G.Y.; Li, D.H.; Wang, X.L. Identification of colorectal cancer using proteomic patterns in serum. Ai Zheng 2004, 23, 614-618 (in Chinese).
71. Habermann, J.K.; Roblick, U.J.; Luke, B.T.; Prieto, D.A.; Finlay, W.J.; Podust, V.N.; Roman, J.M.; Oevermann, E.; Schiedeck, T.; Homann, N. et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006, 131, 1020-1029.
72. Nesvizhskii, A.I.; Vitek, O.; Aebersold, R. Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat. Methods 2007, 4, 787-797.
73. Diamandis, E.P. Validation of breast cancer biomarkers identified by mass spectrometry. Clin. Chem. 2006, 52, 771-772.
74. Melle, C.; Ernst, G.; Schimmel, B.; Bleul, A.; Thieme, H.; Kaufmann, R.; Mothes, H.; Settmacher, U.; Claussen, U.; Halbhuber, K.J. et al. Discovery and identification of alpha- defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005, 129, 66-73.
75. Albrethsen, J.; Bogebo, R.; Gammeltoft, S.; Olsen, J.; Winther, B.; Raskov, H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: A biomarker study. BMC Cancer 2005, doi:10.1186/1471-2407-5-8.
76. Carr, S.; Aebersold, R.; Baldwin, M.; Burlingame, A.; Clauser, K.; Nesvizhskii, A. The need for guidelines in publication of peptide and protein identification data: Working group on publication guidelines for peptide and protein identification data. Mol. Cell Proteomics 2004, 3, 531-533.
77. Anderson, N.L.; Anderson, N.G. The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell Proteomics 2002, 1, 845-867.
78. Liotta, L.A.; Petricoin, E.F. Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J. Clin. Invest. 2006, 116, 26-30.
79. Diamandis, E.P. Peptidomics for cancer diagnosis: Present and future. J. Proteome Res. 2006, 5, 2079-2082.